rupiya.io
⠋Loading...
0%
❯ Fetching latest market data...
Max Healthcare is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Max Healthcare Institute Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,608 Cr | ₹1,729 Cr | ₹1,691 Cr | ||||||
| Expenses | ₹1,467 Cr | ₹1,616 Cr | ₹1,535 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,142 Cr | ₹1,215 Cr | ₹1,285 Cr | ₹1,363 Cr | ||||||||
| Expenses | ₹828 Cr | ₹874 Cr | ₹948 Cr | ₹976 Cr | ||||||||
| Operating Profit | ₹314 Cr | ₹340 Cr | ₹337 Cr | ₹387 Cr |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹537 Cr | ₹537 Cr | ₹537 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹655 Cr | ₹627 Cr | ₹426 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2018 | ₹156 Cr | ₹-104 Cr | ₹-48 Cr | — |
| Mar 2019 | ₹166 Cr | ₹-124 Cr | ₹-48 Cr | — |
| Mar 2020 | ₹89 Cr | ₹-17 Cr | ₹-74 Cr | — |
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 14.3% | 14.2% | 14.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 15.8% | 15.8% | 15.6% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.4 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 7.0 | 7.8 | 11.3 | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹14.56 |
| FY23 | Final | ₹11.46 |
| FY22 | Interim | ₹17.40 |
| FY21 | Final | |
| FY20 | Final | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Max Healthcare's competitive moat, management quality, and growth runway available with Premium.
Premium| Operating Profit | ₹141 Cr | ₹113 Cr | ₹156 Cr |
| OPM % | 9.0% | 7.0% | 9.0% |
| Other Income | ₹59 Cr | ₹65 Cr | ₹56 Cr |
| Depreciation | ₹96 Cr | ₹94 Cr | ₹103 Cr |
| Interest | ₹100 Cr | ₹99 Cr | ₹101 Cr |
| Profit Before Tax | ₹5 Cr | ₹-15 Cr | ₹8 Cr |
| Tax | ₹5 Cr | ₹-15 Cr | ₹8 Cr |
| Net Profit | ₹16 Cr | ₹-25 Cr | ₹0 Cr |
| EPS (₹) | 0.3 | -0.5 | -0.1 |
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 6 more years.
| OPM % | 28.0% | 28.0% | 26.0% | 28.0% |
| Depreciation | ₹57 Cr | ₹60 Cr | ₹56 Cr | ₹58 Cr |
| Interest | ₹20 Cr | ₹20 Cr | ₹19 Cr | ₹9 Cr |
| Net Profit | ₹222 Cr | ₹251 Cr | ₹240 Cr | ₹277 Cr |
| EPS (₹) | 2.3 | 2.6 | 2.5 | 2.9 |
Register free to see 8 more quarters.
| Borrowings | ₹874 Cr | ₹981 Cr | ₹1,003 Cr |
| Other Liabilities | ₹1,080 Cr | ₹1,157 Cr | ₹1,389 Cr |
| Total Liabilities | ₹3,146 Cr | ₹3,302 Cr | ₹3,355 Cr |
| Assets |
| Fixed Assets | ₹2,244 Cr | ₹2,227 Cr | ₹2,192 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹856 Cr | ₹1,036 Cr | ₹1,075 Cr |
| Total Assets | ₹3,146 Cr | ₹3,302 Cr | ₹3,355 Cr |
Register free to see 6 more years.
| Mar 2025 |
Register free to see 6 more years.
| — |
| — |
| — |
| Current Ratio | 1.4 | 1.8 | 1.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.1 | 1.2 | 1.1 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 13.7% | 13.9% | 14.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.2% | 8.4% | 8.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 17.9 | 13.2 | 15.8 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 1.5 | 1.6 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 0.7 | 0.7 | 0.8 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 5.5 | 4.8 | 8.7 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.